ABCL-1492: Mosunetuzumab Plus Polatuzumab Vedotin (MPola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Huilai Zhang, Won-Seog Kim et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Laura Maria Fogliatto, Dai Maruyama et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapyWon-Seog Kim, Jason R. Westin, Huilai Zhang et al.|Blood|2025Cited by 0